Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + paclitaxel + bevacizumab (Gruppo Oncologico dell'Italia Meridionale)
- Development stage
- Unknown
- Lead developer
- Gruppo Oncologico dell'Italia Meridionale
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination chemotherapy regimen consists of carboplatin, paclitaxel, and bevacizumab. It was specifically evaluated by the **Gruppo Oncologico Italia Meridionale (GOIM)** in the ERACLE Phase III trial for the first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC). Carboplatin is a platinum-based alkylating agent that causes DNA cross-linking, paclitaxel is a taxane that stabilizes microtubules to inhibit mitosis, and bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), thereby inhibiting tumor angiogenesis. The regimen typically involves induction with all three agents followed by maintenance therapy with bevacizumab alone.
- Brand names
- Avastin
- Other names
- CPBcarboplatin-paclitaxel-bevacizumabERACLE regimen
02
Targets
Beyond the preview
Go deeper on carboplatin + paclitaxel + bevacizumab (Gruppo Oncologico dell'Italia Meridionale).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + paclitaxel + bevacizumab (Gruppo Oncologico dell'Italia Meridionale).